NM_007194.4(CHEK2):c.1092A>G (p.Ile364Met) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Feb 1, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004517286.1

Allele description [Variation Report for NM_007194.4(CHEK2):c.1092A>G (p.Ile364Met)]

NM_007194.4(CHEK2):c.1092A>G (p.Ile364Met)

Gene:

CHEK2:checkpoint kinase 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

22q12.1

Genomic location:

Preferred name:

NM_007194.4(CHEK2):c.1092A>G (p.Ile364Met)

HGVS:

NC_000022.11:g.28696904T>C
NG_008150.2:g.49963A>G
NM_001005735.2:c.1221A>G
NM_001257387.2:c.429A>G
NM_001349956.2:c.891A>G
NM_007194.4:c.1092A>GMANE SELECT
NM_145862.2:c.1009-1031A>G
NP_001005735.1:p.Ile407Met
NP_001244316.1:p.Ile143Met
NP_001336885.1:p.Ile297Met
NP_009125.1:p.Ile364Met
LRG_302t1:c.1092A>G
LRG_302:g.49963A>G
LRG_302p1:p.Ile364Met
NC_000022.10:g.29092892T>C
NM_007194.3:c.1092A>G

Protein change:

I143M

Molecular consequence:

NM_145862.2:c.1009-1031A>G - intron variant - [Sequence Ontology: SO:0001627]
NM_001005735.2:c.1221A>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001257387.2:c.429A>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001349956.2:c.891A>G - missense variant - [Sequence Ontology: SO:0001583]
NM_007194.4:c.1092A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV005025504	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Feb 1, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV005025504

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Feb 1, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV005025504.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.I364M variant (also known as c.1092A>G), located in coding exon 9 of the CHEK2 gene, results from an A to G substitution at nucleotide position 1092. The isoleucine at codon 364 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: May 7, 2024

ClinVar

Relating variation to medicine